
Sarepta Therapeutics fell 14.0% from $16.48 to $14.17, behind the S&P 500's +9.7%. Its worst day was Feb 5 (−13.7%), and its low came Nov 19 at $14.17.
Story events cover the past 12 months · Times ET
Nov 20, 2025 – Nov 19, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Sarepta Therapeutics closed at its highest level of the year, 44.6% above where the year started.
+2.9% · S&P 500 +0.7%
Sarepta Therapeutics shares fell 13.7%, while the S&P 500 fell 1.2%.
−13.7%, the year's worst day · S&P 500 −1.2%
EPS of $-3.58 missed the $-0.87 estimate on $442.9M revenue (est. $398.0M).
−8.0% · S&P 500 −0.6%
Sarepta Therapeutics shares rose 35.0%, while the S&P 500 rose 0.6%.
+35.0%, the year's best day · S&P 500 +0.6%
EPS of $3.16 beat the $0.91 estimate on $730.8M revenue (est. $473.6M).
−9.7% · S&P 500 −0.3%
EPS of $0.64 beat the $0.46 estimate on $401.3M revenue (est. $364.4M).
+5.3% · S&P 500 −0.2%
EPS of $0.13 missed the $0.32 estimate on $381.4M revenue (est. $349.8M).
+1.4% · S&P 500 +0.3%
Where it ended: a close of $14.17 on Nov 19, 2026. Up next: Q4 2026 earnings on Feb 24, 2027 (EPS est. $-0.15, revenue est. $353.4M).
Nothing in the past 12 months.
All SRPT dividend history